$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000123252423000026 Filed on May 10, 2023

Income Statement

Concept	2023 Q2	2023 Q1
Revenue	$957.3M	$892.8M
YoY Change	2.62%	9.72%
Cost Of Revenue	$97.54M	$128.6M
YoY Change	-21.47%	11.59%
Gross Profit	$859.8M	$764.2M
YoY Change	6.32%	9.41%
Gross Profit Margin	89.81%	85.59%
Selling, General & Admin	$340.8M	$297.9M
YoY Change	-6.99%	-3.53%
% of Gross Profit	39.64%	38.99%
Research & Development	$209.2M	$189.4M
YoY Change	50.48%	45.72%
% of Gross Profit	24.34%	24.79%
Depreciation & Amortization	$159.6M	$7.574M
YoY Change	2.16%	-0.56%
% of Gross Profit	18.56%	0.99%
Operating Expenses	$550.1M	$487.3M
YoY Change	8.82%	11.06%
Operating Profit	$157.6M	$126.1M
YoY Change	84.27%	43.98%
Interest Expense	-$73.47M	-$74.15M
YoY Change	16.27%	4.9%
% of Operating Profit	-46.61%	-58.82%
Other Income/Expense, Net
YoY Change
Pretax Income	$81.78M	$55.10M
YoY Change	289.19%	771.16%
Income Tax	-$24.30M	-$15.30M
% Of Pretax Income	-29.71%	-27.77%
Net Earnings	$104.4M	$69.42M
YoY Change	201.28%	4114.94%
Net Earnings / Revenue	10.91%	7.78%
Basic Earnings Per Share	$1.63	$1.09
Diluted Earnings Per Share	$1.52	$1.04
COMMON SHARES
Basic Shares Outstanding	64.00M shares	63.33M shares
Diluted Shares Outstanding	73.54M shares	73.77M shares

Balance Sheet

Concept	2023 Q2	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.362B	$1.168B
YoY Change	76.63%	137.94%
Cash & Equivalents	$1.282B	$1.168B
Short-Term Investments	$380.0M	$180.0M
Other Short-Term Assets	$272.5M	$245.2M
YoY Change	6.63%	0.56%
Inventory	$657.2M	$674.8M
Prepaid Expenses	$107.5M	$72.78M
Receivables	$610.4M	$623.9M
Other Receivables	$72.80M	$57.22M
Total Short-Term Assets	$3.010B	$2.785B
YoY Change	16.17%	11.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$298.3M	$303.1M
YoY Change	-6.16%	-11.13%
Goodwill	$1.743B	$1.723B
YoY Change	3.26%	-3.31%
Intangibles	$5.706B	$5.764B
YoY Change	-8.53%	-15.02%
Long-Term Investments
YoY Change
Other Assets	$65.98M	$64.08M
YoY Change	90.62%	80.46%
Total Long-Term Assets	$8.251B	$8.262B
YoY Change	-4.17%	-10.85%
TOTAL ASSETS
Total Short-Term Assets	$3.010B	$2.785B
Total Long-Term Assets	$8.251B	$8.262B
Total Assets	$11.26B	$11.05B
YoY Change	0.54%	-6.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$98.43M	$125.5M
YoY Change	32.72%	71.07%
Accrued Expenses	$748.3M	$712.3M
YoY Change	26.15%	17.8%
Deferred Revenue	$4.000K	$4.000K
YoY Change	-99.69%	-99.76%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$31.00M	$31.00M
YoY Change	0.0%	0.0%
Total Short-Term Liabilities	$945.3M	$908.9M
YoY Change	34.0%	23.26%
LONG-TERM LIABILITIES
Long-Term Debt	$5.687B	$5.690B
YoY Change	-5.06%	-5.06%
Other Long-Term Liabilities	$126.7M	$109.2M
YoY Change	-2.11%	-12.41%
Total Long-Term Liabilities	$5.813B	$5.799B
YoY Change	-5.0%	-5.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$945.3M	$908.9M
Total Long-Term Liabilities	$5.813B	$5.799B
Total Liabilities	$6.759B	$6.708B
YoY Change	-0.97%	-2.15%
SHAREHOLDERS EQUITY
Retained Earnings	$811.8M	$803.0M
YoY Change	-18.32%	-16.3%
Common Stock	$3.580B	$3.512B
YoY Change	8.08%	8.41%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.526B	$3.335B
YoY Change
Total Liabilities & Shareholders Equity	$11.26B	$11.05B
YoY Change	0.54%	-6.13%

Cashflow Statement

Concept	2023 Q2	2023 Q1
OPERATING ACTIVITIES
Net Income	$104.4M	$69.42M
YoY Change	201.28%	4114.94%
Depreciation, Depletion And Amortization	$159.6M	$7.574M
YoY Change	2.16%	-0.56%
Cash From Operating Activities	$296.8M	$320.7M
YoY Change	-2.07%	53.46%
INVESTING ACTIVITIES
Capital Expenditures	$5.739M	$3.822M
YoY Change	-107.05%	-68.91%
Acquisitions
YoY Change
Other Investing Activities	-$80.00M
YoY Change	934.13%
Cash From Investing Activities	-$85.74M	-$4.822M
YoY Change	-3.84%	-87.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-96.67M	-$29.79M
YoY Change	-996.98%	-89.0%
NET CHANGE
Cash From Operating Activities	296.8M	$320.7M
Cash From Investing Activities	-85.74M	-$4.822M
Cash From Financing Activities	-96.67M	-$29.79M
Net Change In Cash	114.4M	$286.4M
YoY Change	-49.09%	-384.68%
FREE CASH FLOW
Cash From Operating Activities	$296.8M	$320.7M
Capital Expenditures	$5.739M	$3.822M
Free Cash Flow	$291.0M	$316.9M
YoY Change	-24.3%	61.11%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2022#AccountingStandardsUpdate202006Member
CY2023Q1	us-gaap	Derivative Asset Statement Of Financial Position Extensible Enumeration DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1	us-gaap	Derivative Liability Statement Of Financial Position Extensible Enumeration DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-33500
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1032470
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Fifth Floor, Waterloo Exchange,
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Waterloo Road
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 4
CY2023Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D04 E5W7
CY2023Q1	dei	Country Region CountryRegion	353
CY2023Q1	dei	City Area Code CityAreaCode	1
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	634-7800
CY2023Q1	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value $0.0001 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	JAZZ
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64004791	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1167911000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	881482000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	623938000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	651493000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	674778000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	714061000	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	72779000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	91912000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	245244000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	267192000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	2784650000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2606140000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	227552000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	228050000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	75538000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	73326000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5764209000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5794437000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1723444000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1692662000	usd
CY2023Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	399097000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	376247000	usd
CY2023Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	8559000	usd
CY2022Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	9254000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	64076000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	55139000	usd
CY2023Q1	us-gaap	Assets Assets	11047125000	usd
CY2022Q4	us-gaap	Assets Assets	10835255000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	125454000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	90758000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	712349000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	803255000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	31000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31000000	usd
CY2023Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	40095000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	7717000	usd
CY2023Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	463000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	908902000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	933193000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5689662000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5693341000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	72095000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	71838000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	932247000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	944337000	usd
CY2023Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	109178000	usd
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	106812000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q1	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	usd
CY2022Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	usd
CY2023Q1	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	usd
CY2022Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	usd
CY2023Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3511732000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	3477124000	usd
CY2023Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-980230000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1125509000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	803006000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	733586000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3335041000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3085734000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11047125000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10835255000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	892812000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	813721000	usd
CY2023Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	128644000	usd
CY2022Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	115284000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	297917000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	308813000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	189410000	usd
CY2022Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	129981000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	149786000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172094000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	1000000	usd
CY2022Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	766757000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	726172000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	126055000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	87549000	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-74147000	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-70684000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	3193000	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-10540000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	55101000	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	6325000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15324000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	536000	usd
CY2023Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-1005000	usd
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4142000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	69420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	1647000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63494000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61865000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73771000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62907000	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	69420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	1647000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	145279000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-190488000	usd
CY2023Q1	jazz	Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax	0	usd
CY2022Q1	jazz	Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification Tax OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationTax	43000	usd
CY2023Q1	jazz	Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax	0	usd
CY2022Q1	jazz	Other Comprehensive Income Loss Fair Value Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossFairValueHedgeGainLossAfterReclassificationAndTax	128000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	145279000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-190360000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	214699000	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-188713000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	3085734000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21228000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	43266000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	56646000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	145279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	69420000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	3335041000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3965191000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21729000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	33776000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	50106000	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-190360000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	1647000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	3608487000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	69420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	1647000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	149786000	usd
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	172094000	usd
CY2023Q1	jazz	Inventory Step Up Value Adjustment InventoryStepUpValueAdjustment	60458000	usd
CY2022Q1	jazz	Inventory Step Up Value Adjustment InventoryStepUpValueAdjustment	63943000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	56352000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	50070000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-16773000	usd
CY2022Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	14701000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	7574000	usd
CY2022Q1	us-gaap	Depreciation Depreciation	7617000	usd
CY2023Q1	jazz	Noncash Interest Expense NoncashInterestExpense	4766000	usd
CY2022Q1	jazz	Noncash Interest Expense NoncashInterestExpense	12168000	usd
CY2023Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	2316000	usd
CY2022Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	2170000	usd
CY2023Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	1000000	usd
CY2022Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	0	usd
CY2023Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-66061000	usd
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-45339000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-28460000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9723000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6266000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	24812000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-42032000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-23170000	usd
CY2023Q1	jazz	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-4508000	usd
CY2022Q1	jazz	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-3095000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	9541000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-979000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	34286000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-27617000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-96985000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-23241000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	25413000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	16767000	usd
CY2023Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-459000	usd
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-523000	usd
CY2023Q1	jazz	Increase Decrease In Operating Lease Liabilities Noncurrent IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	-4959000	usd
CY2022Q1	jazz	Increase Decrease In Operating Lease Liabilities Noncurrent IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	-3915000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	1835000	usd
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	5130000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	320708000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	208979000	usd
CY2023Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	1000000	usd
CY2022Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	0	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3822000	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12292000	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2022Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4822000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37292000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	21228000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	21729000	usd
CY2023Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	7750000	usd
CY2022Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	258764000	usd
CY2023Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	43266000	usd
CY2022Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	33776000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-29788000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-270811000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	331000	usd
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1489000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	286429000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-100613000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	881482000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	591448000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1167911000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	490835000	usd
CY2023Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:14pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div>We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes.The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding.We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to our oxybate products, the API is manufactured for us by a single source supplier and the finished products are manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based supplier.
CY2023Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1167911000	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1167911000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1167911000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	881482000	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	881482000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	881482000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	10600000	usd
CY2022Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	usd
CY2022Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5500000	usd
CY2023Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5500000	usd
CY2023Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	25797000	usd
CY2022Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20786000	usd
CY2023Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	510634000	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	517670000	usd
CY2023Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	138347000	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	175605000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	674778000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	714061000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	1692662000	usd
CY2023Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	30782000	usd
CY2023Q1	us-gaap	Goodwill Goodwill	1723444000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	7653789000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1889580000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5764209000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	7506287000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1711850000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5794437000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	455456000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	607275000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	607275000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	607275000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	607275000	usd
CY2023Q1	jazz	Finite Lived Intangible Asset Expected Amortization After Year Four FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour	2879653000	usd
CY2023Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	5764209000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	343692000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization	335697000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	116140000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization	107647000	usd
CY2023Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	227552000	usd
CY2022Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	228050000	usd
CY2023Q1	jazz	Deferred Tax Intercompany Profit Current DeferredTaxIntercompanyProfitCurrent	188028000	usd
CY2022Q4	jazz	Deferred Tax Intercompany Profit Current DeferredTaxIntercompanyProfitCurrent	176057000	usd
CY2023Q1	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	57216000	usd
CY2022Q4	us-gaap	Other Assets Miscellaneous Current OtherAssetsMiscellaneousCurrent	91135000	usd
CY2023Q1	us-gaap	Other Assets Current OtherAssetsCurrent	245244000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	267192000	usd
CY2023Q1	jazz	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	318048000	usd
CY2022Q4	jazz	Accrued Rebates And Other Sales Deductions Current AccruedRebatesAndOtherSalesDeductionsCurrent	313176000	usd
CY2023Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	104914000	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	143243000	usd
CY2023Q1	jazz	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	39806000	usd
CY2022Q4	jazz	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	33205000	usd
CY2023Q1	jazz	Accrued Facilities Expenses Current AccruedFacilitiesExpensesCurrent	30158000	usd
CY2022Q4	jazz	Accrued Facilities Expenses Current AccruedFacilitiesExpensesCurrent	25864000	usd
CY2023Q1	jazz	Sales Return Reserve Current SalesReturnReserveCurrent	28868000	usd
CY2022Q4	jazz	Sales Return Reserve Current SalesReturnReserveCurrent	26164000	usd
CY2023Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	23406000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	22278000	usd
CY2023Q1	jazz	Accrued Clinical Trial Liability Current AccruedClinicalTrialLiabilityCurrent	22182000	usd
CY2022Q4	jazz	Accrued Clinical Trial Liability Current AccruedClinicalTrialLiabilityCurrent	31338000	usd
CY2023Q1	us-gaap	Interest Payable Current InterestPayableCurrent	21481000	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	35614000	usd
CY2023Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	19439000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	57347000	usd
CY2023Q1	jazz	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	17232000	usd
CY2022Q4	jazz	Operating And Finance Lease Liability Current OperatingAndFinanceLeaseLiabilityCurrent	15938000	usd
CY2023Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	12635000	usd
CY2022Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	18553000	usd
CY2023Q1	jazz	Accrued Inventory Related Liabilities Current AccruedInventoryRelatedLiabilitiesCurrent	12631000	usd
CY2022Q4	jazz	Accrued Inventory Related Liabilities Current AccruedInventoryRelatedLiabilitiesCurrent	8565000	usd
CY2023Q1	jazz	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	3327000	usd
CY2022Q4	jazz	Accrued Construction In Progress Current AccruedConstructionInProgressCurrent	3298000	usd
CY2023Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	570000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	57652000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	68672000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	712349000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	803255000	usd
CY2023Q1	us-gaap	Long Term Debt LongTermDebt	5720662000	usd
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	5724341000	usd
CY2023Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	31000000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	31000000	usd
CY2023Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5689662000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	5693341000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	23250000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	606000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	31000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1031000000	usd
CY2023Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	31000000	usd
CY2023Q1	jazz	Long Term Debt Maturity After Year Four LongTermDebtMaturityAfterYearFour	4098500000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	5820750000	usd
CY2023Q1	jazz	Infringed Patents Suit Other Party Counterclaim Number Of Patents Requested To Be Delisted InfringedPatentsSuitOtherPartyCounterclaimNumberOfPatentsRequestedToBeDelisted	1	patent
CY2023Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	145279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	69420000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	1647000	usd
CY2023Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	6963000	usd
CY2022Q1	us-gaap	Interest On Convertible Debt Net Of Tax InterestOnConvertibleDebtNetOfTax	0	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	76383000	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	1647000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63494000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	61865000	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	9044000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2023Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1233000	shares
CY2022Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1042000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	73771000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62907000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.09
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.03
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.04
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.03
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	892812000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	813721000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	892812000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	813721000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	56352000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50070000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8556000	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	8894000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	47796000	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	41176000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-15300000	usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000	usd

Files In Submission

Name	View Source	Status
jazz-20230331_def.xml	Edgar Link	unprocessable
jazz-20230331_cal.xml	Edgar Link	unprocessable
0001232524-23-000026-index-headers.html	Edgar Link	pending
0001232524-23-000026-index.html	Edgar Link	pending
0001232524-23-000026.txt	Edgar Link	pending
0001232524-23-000026-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
jazz-20230331.htm	Edgar Link	pending
jazz-20230331.xsd	Edgar Link	pending
jazzq12023ex311.htm	Edgar Link	pending
jazzq12023ex312.htm	Edgar Link	pending
jazzq12023ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
jazz-20230331_lab.xml	Edgar Link	unprocessable
jazz-20230331_pre.xml	Edgar Link	unprocessable
jazz-20230331_htm.xml	Edgar Link	completed
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2023 Q2 Form 10-Q Financial Statement

#000123252423000026 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2023 Q2 Form 10-Q Financial Statement

#000123252423000026 Filed on May 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz